Health management and monitoring with and without weight loss

• US 20060078497A1
• Filed: 10/07/2005
• Published: 04/13/2006
• Est. Priority Date: 05/13/2004
• Status: Abandoned Application

• Current Assignee: James B. Johnson
• Original Assignee: James B. Johnson
• Inventors: Johnson, James B.
• Application Number:
  US11/246,780
• Publication Number:
  US 20060078497A1
• Time in Patent Office: Days
• US Class Current: 424/9.100
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G16H 20/60 relating to nutrition control, e.g. diets

Abstract

Health management and monitoring predicated on an intermittent calorie restricted health management paradigm is provided. In an illustrative implementation, an intermittent calorie restricted health management program is provided to a participating health management subject so improve the health state of the participating subject (e.g., impact disease states in the health management subject) with or without the participating subject observing weight loss. In the context of health monitoring, in an illustrative operation, the levels of the SIRT-1 protein are measured on the participating health management subject. The measured SIRT-1 protein levels provide an indication of whether the participating health management subject is adhering to the provided intermittent calorie restricted health management paradigm.

Claims

2. A dietary process for achieving reduction of the severity and incidence of diseases comprising any of inflammatory conditions and neurological disorders without weight loss comprising:

(a) providing a selected percentage of a total caloric intake during a first time period T1; and

(b) providing a second selected percentage of the total caloric intake during a second time period T2.

3. The method as recited in claim 2 further comprising providing a value for the total caloric intake from one or more dietary guidelines.

4. The method as recited in claim 2 further comprising providing a value for T2 being greater than or equal to a value for T1.

5. The method as recited in claim 2 further comprising repeating steps (a) and (b).

6. The method as recited in claim 2 further comprising providing a percentage of the total caloric intake during time period T1 such that weight loss is not observed.

7. The method as recited in claim 6 further comprising providing a first percentage of the total caloric intake during time period T1 and a second percentage of the total caloric intake during time period T2 such that the average of the first percentage and second percentage is 100%.

8. A method for monitoring health management comprising:

(a) providing a calorie restricted health management paradigm; and

(b) providing a means for monitoring the activity and/or amount of SIRT-1 protein as an indicator of adherence to the calorie restricted health management paradigm.

9. The method as recited in claim 8 further comprising providing a biochemical means for measuring the activity and/or amount of SIRT-1 protein in a participating subject.

10. The method as recited in claim 9 further comprising providing a biochemical test of white blood cells to measure the activity and/or amount of SIRT-1 protein.

11. The method as recited in claim 8 further comprising adjusting the calorie restricted health management paradigm based on the activity and/or amount of SIRT-1 protein that is measured.

12. The method as recited in claim 8 further comprising measuring the activity and/or amount of SIRT-1 protein as a measure of the state of health for a participating subject.

13. A method for treating diseases using protein monitoring in mammals comprising:

(a) providing an intermittent calorie restricted health management paradigm; and

(b) providing a means for monitoring the activity and/or amount of SIRT-1 as an indicator of the acuity of one or more diseases in a participating subject.

14. The method as recited in claim 13 further comprising providing a biochemical means for measuring the activity and/or amount of SIRT-1 protein in the participating subject.

15. The method as recited in claim 14 further comprising providing a biochemical test of white blood cells to measure the activity and/or amount of SIRT-1 protein.

16. The method as recited in claim 13 further comprising adjusting the treatment of one or more diseases based on the activity and/or amount of SIRT-1 protein that is measured.

17. The method as recited in claim 13 further comprising measuring the activity and/or amount of SIRT-1 protein as a measure of the state of health for a participating subject.

18. The method as recited in claim 14 further comprising monitoring the SIRT-1 protein to create a base line measurement for a participating subject.

19. The method as recited in claim 18 further comprising monitoring the SIRT-1 protein such that an increase in the range of 20% to 50% of the SIRT-1 protein as compared with the base line measurement triggers one more health management decisions.

20. The method as recited in claim 19 further comprising providing a health management decision to a participating subject comprising any of stopping the intermittent calorie restricted health management paradigm, adjusting the intermittent calorie restricted health management paradigm, and maintaining the intermittent calorie restricted health management paradigm.

21. The method as recited in claim 20 further comprising providing an intermittent calorie restricted health management paradigm comprising intaking within a range between 10% to 70% of a total caloric intake for a first portion of a selected time period and intaking within a range between 10%-100% of total caloric intake for a second portion of the selected time period.

22. A method for treating diseases using gene monitoring in mammals comprising:

(a) providing an intermittent calorie restricted health management paradigm; and

(b) providing a means for monitoring the activity and/or amount of PNC-1 as an indicator of the acuity of one or more diseases in a participating subject.

1. A method for accomplishing human weight management comprising:

(a) providing a selected percentage of a total caloric intake during a first time period T1; and

(b) providing a second selected percentage of the total caloric intake during a second time period T2.

23. The method as recited in claim 22 further comprising providing a biochemical means for measuring the activity and/or amount of PNC-1 gene in the participating subject.

24. The method as recited in claim 23 further comprising providing a biochemical test of white blood cells to measure the activity and/or amount of the PNC-1 gene.

25. The method as recited in claim 12 further comprising adjusting the treatment of one or more diseases based on the presence of the PNC-1 gene.

26. The method as recited in claim 23 further comprising monitoring the presence of the PNC-1 gene to create a base line measurement for a participating subject.

27. The method as recited in claim 26 further comprising monitoring the presence of the PNC-1 gene as compared with the base line measurement triggers one more health management decisions.

28. The method as recited in claim 27 further comprising providing a health management decision to a participating subject comprising any of stopping the intermittent calorie restricted health management paradigm, adjusting the intermittent calorie restricted health management paradigm, and maintaining the intermittent calorie restricted health management paradigm.

29. The method as recited in claim 28 further comprising providing an intermittent calorie restricted health management paradigm comprising intaking within a range between 10% to 70% of a total caloric intake for a first portion of a selected time period and intaking within a range between 10%-100% of total caloric intake for a second portion of the selected time period.

25-1. The method as recited in claim 22 further comprising measuring the presence of the PNC-1 gene as a measure of the state of health for a participating subject.